【佳學(xué)基因檢測】金合歡素抑制人肝細(xì)胞癌細(xì)胞系的細(xì)胞增殖并誘導(dǎo)細(xì)胞凋亡

腫瘤基因檢測是什么意思—答案

綜述在《腫瘤致病基因檢測與轉(zhuǎn)移潛能分析》收錄《Molecules》在.?2022 Aug 23;27(17):5361.發(fā)表了一篇題目為《金合歡素抑制人肝細(xì)胞癌細(xì)胞系的細(xì)胞增殖并誘導(dǎo)細(xì)胞凋亡》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Manal Alfwuaires,?Hany Elsawy,?Azza Sedky等完成。促進(jìn)了腫瘤的正確治療與個性化用藥的發(fā)展，進(jìn)一步強調(diào)了基因信息檢測與分析的重要性。

腫瘤靶向藥物及正確治療臨床研究內(nèi)容關(guān)鍵詞：

狀態(tài)3,金合歡素,細(xì)胞凋亡,肝細(xì)胞癌,增殖

腫瘤靶向治療基因檢測臨床應(yīng)用結(jié)果

人類肝細(xì)胞癌 (HCC) 是全球第五大常見癌癥和第三大死亡原因。賊近的證據(jù)表明，STAT3 調(diào)節(jié) HCC 中的增殖、存活、轉(zhuǎn)移和血管生成基因。抑制 STAT3 激活的新型藥物可用于預(yù)防或治療 HCC。我們使用功能性蛋白質(zhì)組學(xué)腫瘤通路技術(shù)平臺和多個 HCC 細(xì)胞系來研究金合歡素 (ACN) 對 STAT3 活化、蛋白激酶、磷酸酶、STAT3 調(diào)節(jié)基因產(chǎn)物和細(xì)胞凋亡的影響。發(fā)現(xiàn) ACN 在 HCC 細(xì)胞中以劑量和時間依賴性方式抑制 STAT3 活化。上游激酶 c-Src、Janus 激活激酶 1 和 Janus 激活激酶 2 也被抑制。釩酸鹽處理消除了 STAT3 的 ACN 抑制，表明酪氨酸磷酸酶活性的參與。發(fā)現(xiàn) ACN 通過 STAT3 抑制抑制參與增殖、存活和血管生成的基因的蛋白質(zhì)表達(dá)。 ACN 似乎是一種新型 STAT3 抑制劑，可能是用于治療 HCC 和其他癌癥的有前途的治療化合物。金合歡素;細(xì)胞凋亡；肝細(xì)胞癌;增殖。

腫瘤發(fā)生與反復(fù)轉(zhuǎn)移國際數(shù)據(jù)庫描述：

Human hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of death across the world. Recent evidence suggests that STAT3 regulates proliferative, survival, metastasis, and angiogenesis genes in HCC. Novel agents that suppress STAT3 activation can be used to prevent or treat HCC. We used a functional proteomics tumor pathway technology platform and multiple HCC cell lines to investigate the effects of acacetin (ACN) on STAT3 activation, protein kinases, phosphatases, products of STAT3-regulated genes, and apoptosis. ACN was found to inhibit STAT3 activation in a dose- and time-dependent manner in HCC cells. Upstream kinases c-Src, Janus-activated kinase 1, and Janus-activated kinase 2 were also inhibited. The ACN inhibition of STAT3 was abolished by vanadate treatment, suggesting the involvement of tyrosine phosphatase activity. ACN was found to suppress the protein expression of genes involved in proliferation, survival, and angiogenesis via STAT3 inhibition. ACN appears to be a novel STAT3 inhibitor and may be a promising therapeutic compound for application in the treatment of HCC and other cancers.Keywords:?STAT3; acacetin; apoptosis; hepatocellular carcinoma; proliferation.